Biotium, a leading supplier and inventor of fluorescent cellular probes for life science research, announces the release of new ExoBrite Antibody Conjugates. These antibodies were curated specifically for optimal detection of exosome markers CD9, CD63, and CD81 in isolated exosomes or exosome extracts with little to no background. ExoBrite™ Antibody Conjugates are available in formulations for both flow cytometry and western blotting.

Extracellular vesicles (EVs), including exosomes, are increasingly studied for their roles in cell communication, and as potential targets for diagnostic and drug delivery applications. The most common proteins used as exosome markers are CD9, CD63, and CD81, members of the tetraspanin family. While antibodies targeting these proteins are available by commercial suppliers, few are validated or perform well for detection of EVs or exosomes. ExoBrite Flow Antibody Conjugates and ExoBrite Western Antibody Conjugates were developed by Biotium scientists for optimal detection of CD9, CD63, and CD81 exosome markers for flow cytometry and western blotting.

ExoBrite Flow Antibodies are designed for detection of isolated or bead-bound EVs by flow cytometry. The antibodies are available in 4 conjugates: ExoBrite 410/450 (Pacific Blue™ channel), ExoBrite 490/515 (FITC channel), ExoBrite 560/585 (PE channel with yellow laser), and ExoBrite R-PE (PE channel). Isotype controls are also available for each conjugate.

ExoBrite Western Antibodies are designed for detection of exosome markers in EV extracts by near-IR fluorescent western blot.